FRANKFURT, Oct 12 Germany’s CureVac said today it is no longer seeking European regulatory approval for its coronavirus vaccine, and will focus instead on a more promising second-generation jab. The decision comes after final trial results in July confirmed that CureVac’s first vaccine had.
Germany's CureVac said Tuesday it is no longer seeking European regulatory approval for its coronavirus vaccine, and will focus instead on a more promising seco
The decision comes after final trial results in July confirmed that CureVac s first vaccine had an efficacy rate of just 48%, well below that of faster rivals Pfizer-BioNTech and Moderna, whose vaccines are based on the same mRNA technology.